Hyponatremia screening: Difference between revisions
Created page with "__NOTOC__ {{Hyponatremia}} {{CMG}}; {{AE}} ==Overview== There is insufficient evidence to recommend routine screening for [disease/malignancy]. OR According to the [guide..." |
|||
Line 15: | Line 15: | ||
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | ||
==Screening== | ==Screening== | ||
Plasma sodium should be check in | |||
* 1–2 weeks after initiation of thiazide, SNRI, and SSRI therapy, especially in patients at high risk for hyponatremia. | |||
* All hospitalized patients on admission | |||
There is insufficient evidence to recommend routine screening for [disease/malignancy]. | There is insufficient evidence to recommend routine screening for [disease/malignancy]. | ||
Revision as of 04:27, 13 May 2018
Hyponatremia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hyponatremia screening On the Web |
American Roentgen Ray Society Images of Hyponatremia screening |
Risk calculators and risk factors for Hyponatremia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
Plasma sodium should be check in
- 1–2 weeks after initiation of thiazide, SNRI, and SSRI therapy, especially in patients at high risk for hyponatremia.
- All hospitalized patients on admission
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]